Meeting
2019 ASCO Annual Meeting
Safety and efficacy of abivertinib (AC0010), a third-generation EGFR tyrosine kinase inhibitor, in Chinese patients with EGFR-T790M positive non-small cell lung cancer (NCSLC).
Authors
Qing Zhou
Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China
Qing Zhou , Lin Wu , Luo Feng , Tongtong An , Ying Cheng , Jianying Zhou , Junling Li , Ji Feng Feng , Li Zhang , Baohui Han , Walson Xu , Lvyu Zhu , Li Xu , Xiao Xu , Feng Roger Luo , Yi-Long Wu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCTNCT02330367
Citation
J Clin Oncol 37, 2019 (suppl; abstr 9091)
DOI
10.1200/JCO.2019.37.15_suppl.9091
Abstract #
9091
Poster Bd #
414
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Phase (Ph) II safety and efficacy results of a single-arm ph ib/II study of capmatinib (INC280) + gefitinib in patients (pts) with EGFR-mutated (mut), cMET-positive (cMET+) non-small cell lung cancer (NSCLC).
First Author: Yi-Long Wu
Poster
2016 ASCO Annual Meeting
BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M+ NSCLC: Efficacy and safety at the RP2D.
First Author: Keunchil Park
Poster
2014 ASCO Annual Meeting
Safety and efficacy of INC280 in combination with gefitinib (gef) in patients with EGFR-mutated (mut), MET-positive NSCLC: A single-arm phase lb/ll study.
First Author: Yi-Long Wu
Poster
2017 ASCO Annual Meeting
Phase 1b/2 trial of ribociclib+binimetinib in metastatic NRAS-mutant melanoma: Safety, efficacy, and recommended phase 2 dose (RP2D).
First Author: Martin H. Schuler